自噬溶酶体胞吐将Src激酶倒置至癌细胞表面

Corleone S. Delaveris et al. INTRODUCTION: Antibody-targeted therapeutics for cancer (e.g., T cell engagers, antibody-based radioligand therapies, and antibody- drug conjugates) require a cancer-associated protein to be displayed on the cell surface at much higher levels than in healthy tissues. Typically, targets are proteins highly up-regulated by cancer cells for survival (e.g., HER2 and EGFR). However, therapies targeting these proteins are limited by the expression of these cell surface targets in healthy tissues. There is therefore a need to find and understand new classes of tumor-associated cell surface proteins that have greater differences in tumor versus healthy tissue expression. …